Laserenucleation of Prostate Glands > 60g

Laserenucleation of Prostate Glands > 60g - ThuVEP vs. HoLEP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000787

Enrollment

120

Registered

2011-05-16

Start date

2010-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N40

Interventions

Group 1: Thulium VapoEnucleation of the Prostate Group 2: Holmium Laserenucleation of the prostate

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: IPSS-Score = 8 Uroflow: Qmax = 15ml/s Urodynamic: Schäfer-Scale = II° Prostate volume measured by transrectal ultrasoundl (TRUS) = 60 ml

Exclusion criteria

Exclusion criteria: Known urethral or prostate surgery Voiding symptoms not referred to BPO (Striktur) Known Prostate Cancer Neurogenic Bladder

Design outcomes

Primary

Measure	Time frame
primary outcome: improvement of Qmax and IPSS score minimal improvement: - Qmax 3 ± 5 ml/s - minimum decrease of IPSS-Score: 2 points. Follow-up visit: - 3, 6 months, 1, 2 und 5 years after surgery	—

Secondary

Measure	Time frame
intra and postoperative complications during follow up. Follow-up visit: - 3, 6 months, 1, 2 und 5 years after surgery	—

Countries

Germany

Contacts

Public Contactchristopher netsch

Asklepios Klinik Barmbek Abteilung für Urologie

c.netsch@asklepios.com49 40 1818 82 8042

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026